Neoadjuvant checkpoint blockade in combination with Chemotherapy in patients with tripe-negative breast cancer: exploratory analysis of real-world, multicenter data

被引：0
作者：
Heran Deng
Liying Wang
Na Wang
Kejin Zhang
Yanxia Zhao
Pengfei Qiu
Xiaowei Qi
Danhua Zhang
Fei Xu
Jieqiong Liu
机构：
[1] Sun Yat-Sen Memorial Hospital,Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center
[2] Sun Yat-Sen University,State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine
[3] Sun Yat-Sen University Cancer Center,undefined
[4] Sun Yat-Sen University,undefined
[5] Xiangya Hospital of Central South University,undefined
[6] Center South University,undefined
[7] Union Hospital Tongji Medical College Huazhong University of Science and Technology,undefined
[8] Huazhong University of Science and Technology,undefined
[9] Shandong Tumor Hospital,undefined
[10] Shandong university,undefined
[11] The Southwest Hospital of AMU,undefined
[12] Army Medical University,undefined
[13] The Second Xiangya Hospital of Central South University,undefined
[14] Center South University,undefined
来源：
BMC Cancer | / 23卷
关键词：
Tripe-negative breast cancer; Neoadjuvant immunotherapy; Anti-PD-1/L1 antibody; Real-world study;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 363 条
[1]  
Fan L(2014)Breast cancer in China Lancet Oncol 15 e279-e289
[2]  
Strasser-Weippl K(2020)Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer Drug Des Devel Ther 14 2423-2433
[3]  
Li JJ(2021)The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition Ann Oncol 32 1236-1244
[4]  
St Louis J(2013)Oncology meets immunology: the cancer-immunity cycle Immunit 39 1-10
[5]  
Finkelstein DM(2018)Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents Biochim Biophys Acta Rev Cancer 1869 78-84
[6]  
Yu KD(2021)The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives Clin Immunol 226 108707-1828
[7]  
Chen WQ(2020)Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomized, placebo-controlled, double-blind, phase 3 clinical trial Lancet 396 1817-567
[8]  
Shao ZM(2022)Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer N Engl J Med 386 556-2121
[9]  
Goss PE(2018)Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer N Engl J Med 379 2108-993
[10]  
Wang H(2021)First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis Ann Oncol 32 983-684
12345678910